Switch View
© Globe Newswire
27.10.2025
ISIN: US03843E1047
Aquestive Therapeutics Inc
AQST
LISTED
NASDAQ
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
News Preview
WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended Se...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
ISIN: US67080M1036
Nurix Therapeutics Inc
NRIX
LISTED
NASDAQ
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
News Preview
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of its previously announced underwritten registe...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
News Preview
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
27.10.2025
ISIN: US7140461093
Revvity Inc
RVTY
LISTED
NYSE
Revvity Announces Financial Results for the Third Quarter of 2025
News Preview
Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025.
The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from con...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
27.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”), have until December 15, 2025 to seek appointment as lead plaintiff of the Baxter class action lawsuit. Captioned Electrical W...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
ISIN: FR0000121667
EssilorLuxottica SA
EL
LISTED
EURONEXT
Roger Federer Foundation Partners with OneSight EssilorLuxottica Foundation to Bring Vision Care to Thousands of Zambian Schoolchildren
News Preview
Roger Federer Foundation Partners with OneSight EssilorLuxottica Foundation to Bring Vision Care to Thousands of Zambian Schoolchildren...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: SE0022419784
Sectra AB
SECT_B
LISTED
STO
Stockholm hospitals unify all imaging in Sectra's cloud service to boost collaboration and patient care
News Preview
LINKÖPING, Sweden, Oct. 27, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra(STO: SECT B) announces that Sweden's capital region, Region Stockholm, will expand its use of Sectra's enterprise imaging solution and transition to a fully managed cloud service. All hospitals in Re...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pr...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics " or "the Company") (NASDAQ: CYTK ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
27.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. ("Savara " or "the Company") (NASDAQ: SVRA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and E...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus " or "the Company") (NASDAQ: LNTH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Se...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the Company") (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promul...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Semler Scientific, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SMLR
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Semler Scientific, Inc. ("Semler " or "the Company") (NASDAQ: SMLR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Secu...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Semler Scientific, Inc. ("Semler" or "the Company") (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LFMD
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD " or "the Company") (NASDAQ: LFMD ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD" or "the Company") (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promu...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.10.2025
ISIN: US74366E1029
Protagonist Therapeutics Inc
PTGX
LISTED
NASDAQ
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
News Preview
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placeboUpdated ANTHEM-UC data support Phase 3 clinical development of icotrokinra in both moderately to severely active ulcerati...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
News Preview
Fortschritte in der präklinischen Pipeline zur Bekämpfung neurodegenerativer Erkrankungen
Evotec erhält eine Zahlung von 25 Mio. US$, um die weitere Entwicklung gemeinsamer Programme zu unterstützen
Hamburg, 27. Oktober 2025:
Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 5664......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
News Preview
Advances made in preclinical pipeline addressing neurodegenerative diseases
Evotec receives US$ 25 m payment to support continued progression of joint programs
Hamburg, Germany, 27 October 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced t......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.10.2025
ISIN: US03209R1032
Amphastar Pharmaceuticals Inc
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September 30, 2025, after the market closes on Thursday, November 6, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: AU000000CSL8
CSL Limited
CSL
LISTED
ASX
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
News Preview
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing
BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 /PRNewswire/ -- CSL's base fractionation facility in Broadmeadows, Australia has been recognis...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: AU000000CSL8
CSL Limited
CSL
LISTED
ASX
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
News Preview
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing
BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 /PRNewswire/ -- CSL's base fractionation facility in Broadmeadows, Australia has been recognis...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Health Canada Grants Authorization for Leqembi® (lecanemab)
News Preview
STOCKHOLM, Oct. 27, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment o...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Health Canada Grants Authorization for Leqembi® (lecanemab)
News Preview
STOCKHOLM, Oct. 26, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment o...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: AU000000CSL8
CSL Limited
CSL
LISTED
ASX
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
News Preview
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing
BROADMEADOWS, AUSTRALIA, Oct. 26, 2025 /PRNewswire/ -- CSL's base fractionation facility in Broadmeadows, Australia has been recognis...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: KYG0330A1013
Alphamab Oncology
9966
LISTED
HKSE
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer
News Preview
SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Gro...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.10.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
News Preview
Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that the...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
News Preview
The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group
DREAMS-3 is the world's first Phase 3 clinical trial of a GC...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.10.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
News Preview
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology In Canada, lecanemab is indicated for the treatment of adult...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.10.2025
ISIN: US92854B1098
Vivani Medical, Inc.
VANI
LISTED
NASDAQ
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
News Preview
ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 6,000,000 shares of its common stock at an offering price...
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
ISIN: IE00BTN1Y115
Medtronic PLC
MDT
LISTED
NYSE
Three-year SPYRAL HTN-ON MED results show sustained, 18 mmHg office-based blood pressure reductions
News Preview
Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications...
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD Deadline: LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Oct. 26, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD)...
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
ISIN: CNE100003PJ8
Venus Medtech Hangzhou Inc
2500
LISTED
HKSE
Cardiovalve schließt die Rekrutierung für die TARGET-Studie zur CE-Zulassung für den Trikuspidalklappenersatz ab
News Preview
Das Unternehmen nähert sich der Einreichung für die europäische CE-Kennzeichnung mit 150 eingeschriebenen Patienten und ist auf Kurs für die Markteinführung im Jahr 2027
HANGZHOU, China, 26. Oktober 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, im...
Themefolio
Profiler
Peergroup
© BusinessWire
26.10.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Frida...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.10.2025
ISIN: US14843C1053
Castle Biosciences Inc
CSTL
LISTED
NASDAQ
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
News Preview
Castle announced new data on its TissueCypher® Barrett’s Esophagus test being presented at ACG 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
ISIN: US05370A1088
Avidity Biosciences Inc
RNA
LISTED
NASDAQ
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
News Preview
Novartis to acquire Avidity
for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion
Avidity expects to separate its early-stage precision cardiology programs
into a new company ("SpinCo")...
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
SAN DIEGO, Oct. 26, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), have until December 15, 2025 to seek a...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.10.2025
ISIN: US31189P1021
Fate Therapeutics Inc
FATE
LISTED
NASDAQ
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
News Preview
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy...
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
ISIN: US8753721047
Tandem Diabetes Care Inc
TNDM
LISTED
NASDAQ
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
News Preview
NEW YORK, Oct. 26, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
ISIN: CNE100003F19
Wuxi Apptec Co., Ltd.
2359
LISTED
HKSE
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
News Preview
Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY;
Revenue from Continuing Operations[1]Reached RMB12.04 Billion, Up 19.7% YoY...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.10.2025
ISIN: HK0000145638
Beijing Tong Ren Tang Chinese Medicine Co Ltd
3613
LISTED
HKSE
Deep-Rooted in Community Caring for a Decade 'Tong Ren Tang Stroke Prevention Campaign' Debuts on Campus
News Preview
EQS Newswire / 26/10/2025 / 07:45 CET/CEST
Inaugural "Hong Kong Student Ambassador Programme for Chinese Medicine and Health Care" Graduation Ceremony Students Showcase Their Learning Outcomes HONG KONG SAR - Media OutReach Newswire - 26 October 2025 - Beijing Tong Ren Tang Chinese Medicine Company Limited ("Beijing Tong Ren Tang") (3613.HK) ......
Themefolio
Profiler
Peergroup
© BusinessWire
26.10.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
News Preview
Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data wil...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2025
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
News Preview
Gerresheimer AG: Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
Duesseldorf, October 25, 2025. Today, Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") obtained initial findings from an investigation by an external, independent law firm, which the com......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2025
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Erste Erkenntnisse einer externen unabhängigen Untersuchung zur Umsatzrealisierung aus Bill-and-Hold- Vereinbarungen im Geschäftsjahr 2024
News Preview
Gerresheimer AG: Erste Erkenntnisse einer externen unabhängigen Untersuchung zur Umsatzrealisierung aus Bill-and-Hold- Vereinbarungen im Geschäftsjahr 2024
Düsseldorf, 25. Oktober 2025. Die Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer"), hat heute erste Erkenntnisse aus einer von der Gesellschaft eingeleiteten externen, unabhängigen Untersu......
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: BE0003739530
UCB SA
UCB
LISTED
EURONEXT
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
News Preview
Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained inflammation c...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced updated data and first disclosure of results in chronic, refractory autoimmune diseases from the Phase 1 Breakfree-1 study (NCT05869955) of its investigational, autologous CD19-targeted NEX-T™ CAR T cell therapy BMS-986353 (CC-97540). The data, evaluating a total of 71 treated patients across the sy...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
News Preview
NEW YORK, Oct. 25, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf o...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: US2300311063
Cullinan Therapeutics Inc
CGEM
LISTED
NASDAQ
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
News Preview
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
News Preview
NASP data highlight reduction in disease burden among people living with uncontrolled gout...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: US5019761049
Kyverna Therapeutics, Inc.
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
News Preview
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: US71722W1071
Phathom Pharmaceuticals Inc
PHAT
LISTED
NASDAQ
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
News Preview
FLORHAM PARK, N.J., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (von...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
ISIN: NL0011606264
Merus N.V.
MRUS
LISTED
NASDAQ
Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid
News Preview
– 100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd)...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: CNE100003PJ8
Venus Medtech Hangzhou Inc
2500
LISTED
HKSE
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
News Preview
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch
HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announc...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: CNE100003PJ8
Venus Medtech Hangzhou Inc
2500
LISTED
HKSE
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
News Preview
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch
HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter ref...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: CNE100003PJ8
Venus Medtech Hangzhou Inc
2500
LISTED
HKSE
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
News Preview
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch
HANGZHOU, China, Oct. 25, 2025 /CNW/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred t...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: US34965KAA51
Fortrea Holdings Inc
FTRE
LISTED
NASDAQ
Fortrea Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortrea Holdings, Inc. - FTRE
News Preview
NEW YORK and NEW ORLEANS, Oct. 24, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Fortrea Holdings, Inc. (NasdaqGS: FTRE)....
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Molina Healthcare, Inc. - MOH
News Preview
NEW YORK and NEW ORLEANS, Oct. 24, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilDecember 2, 2025 to file lead plaintiff applications in a securities class action lawsuit against Molina Heal...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
